Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV).

Results from three additional Phase 1 studies demonstrated that the combination of BEM/RZR had a low risk of drug-drug interactions (DDIs) and supported the safety of the regimen of BEM/RZR in ...

Hepatitis C is a serious condition that can greatly affect your liver and overall health. The culprit is a virus called hepatitis C virus (HCV), which typically gets into a person’s system ...

Please provide your email address to receive an email when new articles are posted on . HCV screening increased after guidelines updated to screen all adults and during each pregnancy. Screening ...

When managing patients with hepatitis C virus (HCV), initiating treatment of the infection promptly is more important than determining the severity of their liver disease with the customary ...

Credit: Cepheid. The Xpert HCV test delivers results in about an hour. The Food and Drug Administration (FDA) has granted marketing authorization to Xpert ® HCV, a point-of-care hepatitis C virus ...

The hepatitis C virus (HCV) causes hepatitis C. There are different types or genotypes of hepatitis C, the most common being genotypes 1, 2, and 3. The genotype determines treatment, but generally ...

In a recent study published in the npj vaccines journal, researchers assessed the immune protection elicited by messenger ribonucleic acid (mRNA) vaccines delivering Hepatitis C virus (HCV ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

Low hepatitis C virus (HCV) reinfection rates were shown in patients who inject drugs (PWID) after successful treatment with direct-acting antiviral (DAA) medications, according to study findings ...

Hepatitis C is a liver disease that occurs due to the hepatitis C virus (HCV). Approximately 58 million people globally have a chronic HCV infection. The World Health Organization notes that 1.5 ...